Incyte | INCY - Ordinary Share Capital


Incyte reported $198.46M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 168.71M 104K Sep/2025
Agenus USD 266K 30K Mar/2025
Agios Pharmaceuticals USD 58.45M 169K Dec/2025
Alnylam Pharmaceuticals USD 132.38M 585K Dec/2025
Amgen USD 539M 1000K Dec/2025
BioCryst Pharmaceuticals USD 1.9M 3K Sep/2023
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 192.3M 201K Dec/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Exelixis USD 268.1M 2.03M Sep/2025
Gilead Sciences USD 1.24B 1000K Dec/2025
Incyte USD 198.46M 2.33M Dec/2025
Ionis Pharmaceuticals USD 161.14M 160.98M Sep/2025
MacroGenics USD 63.26M 62.63M Sep/2025
Merck USD 2.49B 15.79M Sep/2025
Moderna USD 391M 2M Sep/2025
Nektar Therapeutics USD 19K 0 Sep/2024
Neurocrine Biosciences USD 100.1M 400K Dec/2025
Novartis USD 1.94B 23.4M Jun/2025
Novartis USD 1.92B 17.06M Sep/2025
Pfizer USD 5.69B 1000K Sep/2025
PTC Therapeutics USD 81.47M 1.54M Dec/2025
Puma Biotechnology USD 5K 0 Jun/2024
Regeneron Pharmaceuticals USD 105.3M 1.1M Sep/2025
Sarepta Therapeutics USD 104.77M 7.06M Sep/2025
Ultragenyx Pharmaceutical USD 96.44M 88K Sep/2025
Vertex Pharmaceuticals USD 254M 0 Dec/2025